Inventor · disambiguated record
Edward Burgard
Also filed as: BURGARD EDWARD C
8 granted patents·21 pending applications·90 citations·filing 1998–2018
86Inventor score
Files withDYNOGEN PHARMACEUTICALS INC20ABBOTT LAB2DYNOGEN PHARMACUETICALS INC2FRASER MATTHEW O2ASTELLAS PHARMA INC1
Top patents by PatentIndex Score
29 records- 0195US7041704B2Methods of treating gastrointestinal tract disorders using sodium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2005·Granted May 9, 2006·34 cites·9 claims
- 0283US7459430B2Methods of using ziconotide to treat overactive bladderDYNOGEN PHARMACEUTICALS INC·Filed 2006·Granted Dec 2, 2008·2 cites·14 claims
- 0383US7084116B2Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2004·Granted Aug 1, 2006·13 cites·14 claims
- 0480US7125848B2Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2004·Granted Oct 24, 2006·9 cites·14 claims
- 0568US7223754B2Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disordersDYNOGEN PHARMACEUTICALS INC·Filed 2004·Granted May 29, 2007·1 cites·16 claims
- 0667US6214581B1Nucleic acids encoding a functional human purinoreceptor P2X3 and P2X6, and methods of production and use thereofABBOTT LAB·Filed 1998·Granted Apr 10, 2001·19 cites·14 claims
- 0766US2009203792A1Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 0863US2007066597A1Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disordersDYNOGEN PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 0961US2005107353A1Methods of treating lower urinary tract disorders using losigamoneDYNOGEN PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 1060US2008275080A1Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulatorsDYNOGEN PHARMACUETICALS INC·Filed 2008·Application pending·0 cites
- 1160US2008085916A1Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1259US2004209960A1Methods of treating lower urinary tract disorders using sodium channell modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 1358US2004213842A1Methods of treating gastrointestinal tract disorders using sodium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 1458US2006188575A1Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 1558US2005054725A1Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 1657US2007060652A1Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 1756US6242216B1Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereofABBOTT LAB·Filed 1998·Granted Jun 5, 2001·12 cites·20 claims
- 1856US2005228049A1Methods for decreasing detrusorDYNOGEN PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1956US2004142034A1Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2003·Application pending·0 cites
- 2056US2006247311A1Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2155US2005113421A1Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disordersDYNOGEN PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 2254US2005239890A1Methods for decreasing detrusor muscle overactivityDYNOGEN PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 2352US2004198822A1Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulatorsDYNOGEN PHARMACUETICALS INC·Filed 2004·Application pending·0 cites
- 2452US2011294881A1METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORSFRASER MATTHEW OLIVER·Filed 2011·Application pending·0 cites
- 2551US2007105785A1Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulatorsDYNOGEN PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2648US2006276542A1Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulatorsFRASER MATTHEW O·Filed 2004·Application pending·0 cites
- 2748US2006264509A1Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulatorsFRASER MATTHEW O·Filed 2004·Application pending·0 cites
- 2842US11352391B2Compositions for inducing urinary voiding and defecationDIGNIFY THERAPEUTICS LLC·Filed 2018·Granted Jun 7, 2022·0 cites·19 claims
- 2941US2015368220A1Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, and method for screening compound comprised in said pharmaceutical compositionASTELLAS PHARMA INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Edward Burgard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →